about
Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?Neonatal thrombocytopenia and megakaryocytopoiesis.Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.Effects of in vitro adult platelet transfusions on neonatal hemostasisDistinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice.Long-term results of prednisone treatment for the anemia of myelofibrosis.An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodiesEvaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 in GNB3.Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction.Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain.Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors.Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites.Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.[Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms].Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemiaAssessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia veraCorrection of anaemia on dialysis: did we forget physiology?
P50
Q33389236-8541240B-23A8-43E2-9BC4-C46D448F6E0AQ33390642-DD12B69D-BA99-41CD-96EF-7A52C764D69DQ33394052-9DC92880-D2F4-4846-B1D5-5BBC4622A75CQ33394140-117DCDE6-95A5-4C93-A4B2-C33131ED14D3Q33409352-F04F2757-FB98-473D-82DC-7845E3EB9C49Q33422565-ACCFB7FE-27F5-4163-ACF9-67404232D7AEQ33422982-760D7A88-A14C-4467-9EE1-119017C1F919Q33424728-5C4FB508-AD83-428E-8770-D15C5A9F5DB3Q34996505-02905B07-9822-40B3-A2F2-273C5D170B52Q37228334-39829A4B-0C86-48CB-9CA0-76DFBBCA281BQ39069010-F6A63149-7EEB-4EDB-9084-4608C08D1D67Q40560173-7D6F04AF-CED8-42C3-A4CA-5FA781D1D74EQ40756300-C73EC6B5-75FF-48E2-8AE4-163EE57F949CQ40916710-EF22B301-6FFC-41C2-A15F-AA129DEEB305Q42385052-FF1A4AE4-1242-4F0D-B9EA-9D3E754D421CQ42854495-49D04CBE-6D39-472D-A70B-E8CF79E8A09FQ45358890-0D6D5208-4558-4052-874E-4ED7BDE5906BQ48080404-58D54906-636B-497F-901B-7675F024FA08Q48100617-C23B80E6-63EA-4C63-8167-F6B4315C4EB6Q48264389-0F804B7D-5E30-4CE8-9C03-CB07F7DA31C7Q48778777-544E4423-01C4-47F4-9EEB-6D196B9E1313Q53131035-55AA31CD-5FCC-4BA8-AA16-F0DB3879419CQ53146385-F765D424-6128-4F5B-A72F-2F66A8CF2B65Q53796449-B3121BFA-EACD-4AED-B44D-79F7C0C4852FQ54261864-DBDFD907-E151-4A5E-9AC8-C6BC71343C25Q54294878-2F8ED75C-7702-4735-B3D7-8D6A8AEC9F1CQ54341051-52AA3391-E735-4EA0-9582-C7F65233F106Q55069465-8353E8DC-DE32-48CD-8472-1DF6A0D6D871Q61145860-AD23FC15-CDA5-4E2A-9365-2ECC699E1A36Q61146044-2A6314CF-B850-4B81-92C7-C66D15AF7B77Q61146076-14D67F27-D7AF-4FC6-93C2-E8C69661319C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francisca Ferrer-Marín
@ast
Francisca Ferrer-Marín
@en
Francisca Ferrer-Marín
@es
Francisca Ferrer-Marín
@nl
Francisca Ferrer-Marín
@sl
type
label
Francisca Ferrer-Marín
@ast
Francisca Ferrer-Marín
@en
Francisca Ferrer-Marín
@es
Francisca Ferrer-Marín
@nl
Francisca Ferrer-Marín
@sl
prefLabel
Francisca Ferrer-Marín
@ast
Francisca Ferrer-Marín
@en
Francisca Ferrer-Marín
@es
Francisca Ferrer-Marín
@nl
Francisca Ferrer-Marín
@sl
P1053
M-5850-2017
P106
P1153
35799658800
P21
P31
P3829
P496
0000-0002-9520-3243